Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Mar 26, 2009


Total compensation of Life Technologies CEO Greg Lucier shrunk 13 percent in 2008 to more than $9.6 million, according to the company's proxy filed last week with the US Securities and Exchange Commission.

The brunt of the decrease in compensation stems from a reduction in option awards of almost $1.6 million in 2008 from more than $3 million in 2007. His 2008 compensation includes a base salary of $978,404, stock awards of more than $4.9 million, and non-equity incentive plan compensation of $2.05 million.

Mark Stevenson, president and chief operating officer of the company, received total compensation of about $7.7 million in 2008, including a base salary of $75,000, a bonus of more than $6.7 million, and a non-equity incentive plan compensation of $709,122, according to Life Tech's proxy. His base salary consisted of payments for the last five weeks of 2008 that Applied Biosystems was part of Life Tech.

Stevenson had been president and COO of ABI before it merged with Invitrogen creating Life Tech.

In addition, David Hoffmeister, chief financial officer of the firm, was paid a total of nearly $3.5 million last year. His base salary was $475,192. He also received option awards of almost $2 million.

The company will hold its annual shareholder meeting on April 30 at its headquarters in Carlsbad, Calif. Its proxy can be viewed on line here.

Bruker last week appointed Brian Monahan chief accounting officer and vice president of finance.

Monahan had been corporate controller at Bruker since joining the company in April 2004. He also is an executive vice president at Bruker Daltonics, a position he's held since November 2006.

Prior to Bruker, Monahan was at Fisher Scientific where he was manager of accounting and financial reporting.

Eric Fung has resigned as Vermillion's vice president and chief scientific officer, the company said in a document filed with the US Securities and Exchange Commission this week.

The company did not name a replacement.

In the filing, Vermillion said that Fung left for personal reasons "and not the result of any disagreement with the company."

Fung joined the company as a lead scientist in its Biomarker Discovery Center laboratories in 2000 when it was called Ciphergen Biosystems. In 2006, he was promoted to CSO.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.